ALIVUS

Alivus Life Sciences Share Price

₹1,081.15 +19.5 (1.84%)

29 Mar, 2025 04:25

SIP TrendupStart SIP in ALIVUS

Start SIP

Performance

  • Low
  • ₹1,066
  • High
  • ₹1,139
  • 52 Week Low
  • ₹744
  • 52 Week High
  • ₹1,335
  • Open Price₹1,093
  • Previous Close₹1,062
  • Volume385,896

Investment Returns

  • Over 1 Month + 18.22%
  • Over 3 Month + 9.48%
  • Over 6 Month + 4.94%
  • Over 1 Year + 40.31%
SIP Lightning

Smart Investing Starts Here Start SIP with Alivus Life Sciences for Steady Growth!

Invest Now

Alivus Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 30
  • PEG Ratio
  • -2
  • Market Cap Cr
  • 13,248
  • P/B Ratio
  • 5.2
  • Average True Range
  • 62.67
  • EPS
  • 36.05
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.47
  • RSI
  • 53.63
  • MFI
  • 74.78

Alivus Life Sciences Financials

Alivus Life Sciences Technicals

EMA & SMA

Current Price
₹1,081.15
+ 19.5 (1.84%)
pointer
  • stock-down_img
  • Bearish Moving Average 1
  • stock-up_img
  • Bullish Moving Average 15
  • 20 Day
  • ₹1,049.72
  • 50 Day
  • ₹1,055.82
  • 100 Day
  • ₹1,054.94
  • 200 Day
  • ₹1,012.28

Resistance and Support

1095.52 Pivot Speed
  • R3 1,198.43
  • R2 1,168.92
  • R1 1,125.03
  • S1 1,051.63
  • S2 1,022.12
  • S3 978.23

What's your outlook on Alivus Life Sciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Glenmark Life Sciences develops and manufactures high-quality Active Pharmaceutical Ingredients (APIs), supplying over 130 molecules to more than 700 global pharmaceutical companies. With world-class manufacturing and research capabilities, GLS focuses on operational excellence, regulatory compliance, and innovation.

Alivus Life Sciences Limited has an operating revenue of Rs. 2,273.94 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 28% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 20% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 54 which is a POOR score indicating inconsistency in earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 23 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Alivus Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-23 Quarterly Results
2024-10-24 Quarterly Results
2024-07-25 Quarterly Results
2024-04-25 Audited Results
2024-01-23 Quarterly Results
Date Purpose Remarks
2023-10-17 INTERIM Rs.22.50 per share(1125%)Interim Dividend
2023-03-24 INTERIM Rs.21.00 per share(1050%)Interim Dividend
2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend
View More

Alivus Life Sciences F&O

Alivus Life Sciences Shareholding Pattern

75%
3.23%
0.22%
6.74%
10.99%
3.82%

About Alivus Life Sciences

  • NSE Symbol
  • ALIVUS
  • BSE Symbol
  • 543322
  • Managing Director & CEO
  • Dr. Yasir Rawjee
  • ISIN
  • INE03Q201024

Similar Stocks to Alivus Life Sciences

Alivus Life Sciences FAQs

Alivus Life Sciences share price is ₹1,081 As on 29 March, 2025 | 04:11

The Market Cap of Alivus Life Sciences is ₹13248.1 Cr As on 29 March, 2025 | 04:11

The P/E ratio of Alivus Life Sciences is 30 As on 29 March, 2025 | 04:11

The PB ratio of Alivus Life Sciences is 5.2 As on 29 March, 2025 | 04:11

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23